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background: Pediatric hypertension has increased in prevalence over the last several decades. While the diagnosis of hypertension 
is made based upon published guidelines, existing guidelines do not specify which anti-hypertensive medications to use as first-line. 
Furthermore, there are no published guidelines regarding the pharmacologic management of children who require additional anti-
hypertensive agents. The purpose of our study was to describe initial pharmacologic management, frequency and type of additional 
anti-hypertensive medication prescribed, and characteristics of children requiring multiple anti-hypertensive agents. We also describe the 
prevalence of end organ injury and associated risk factors among children requiring multiple anti-hypertensive agents.
Methods: Retrospective study of children 10 to 19 years of age with a primary diagnosis of non-renovascular hypertension.
Results: A total of 402 children ages 10 to 19 years with a primary diagnosis of hypertension were seen at our institution between July 
2013 and September 2014. Twenty-two (5.5%) received multiple anti-hypertensive agents for the treatment of refractory hypertension. 
Children requiring multiple anti-hypertensive agents were non-Hispanic black (77%) with a median age of 17 years. The median body mass 
index was 99 percent. Angiotensin converting enzyme inhibitors were the most commonly prescribed first-line medications (64%). Other 
first line agents included calcium channel blockers (22.5%) and hydrochlorothiazide (14%). Comorbidities occurred but were reported in 
fewer than 50% of cases. Medical non-compliance likely played a role in poor response to initial anti-hypertensive use, but could not be 
fully assessed due to the retrospective study design. Second-line anti-hypertensive therapies included lisinopril/hydrochlorothiazide and 
calcium channel blockers.
conclusion:  The need for more than one anti-antihypertensive agent in the management of hypertensive children is not uncommon. 
Better understanding of the risk factors, associated co-morbidities, factors related to medical non-compliance and prescribing practices of 
treating physicians may lead to improved outcome.
